Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced it has formed an agreement with the Texas Department of State Health Services (DSHS) to provide COVID-19...
A new Quest Diagnostics Health Trends® report developed in collaboration with the Centers for Disease Control and Prevention (CDC) found that the COVID-19 pandemic reduced routine hepatitis C virus (HCV) testing and treatment.
Quest Diagnostics has introduced a new COVID-19 testing service that aids in providing insight into an individual's immune response as a result of a recent or prior infection with SARS-CoV-2, the virus that causes COVID-19, or to immune response ...
Quest Diagnostics has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Quest Diagnostics Self-Collection Kit for COVID-19.
Quest Diagnostics is the first national laboratory provider in the United States to enable accurate nonfasting lipid testing using the novel method in patient testing